Search

Novo Nordisk A-S (Class B)

Geschlossen

341.35 -0.28

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

340.8

Max

343.3

Schlüsselkennzahlen

By Trading Economics

Einkommen

-2.5B

27B

Verkäufe

-1.2B

77B

KGV

Branchendurchschnitt

14.432

37.461

EPS

5.96

Dividendenrendite

3.4

Gewinnspanne

34.484

Angestellte

78,387

EBITDA

44B

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+9.53% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

3.40%

2.33%

Nächstes Ergebnis

5. Nov. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

138B

1.5T

Vorheriger Eröffnungskurs

341.63

Vorheriger Schlusskurs

341.35

Novo Nordisk A-S (Class B) Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

17. Okt. 2025, 10:26 UTC

Wichtige Markttreiber

Ozempic Maker Novo Nordisk Shares Fall as Trump Moves to Cut Price of Weight-Loss Drugs

17. Okt. 2025, 10:25 UTC

Wichtige Markttreiber

Ozempic Maker Novo Nordisk Shares Fall as Trump Moves to Cut Price of Weight-Loss Drugs

15. Okt. 2025, 15:36 UTC

Akquisitionen, Fusionen, Übernahmen

Novo Nordisk to Buy Blood Disease Drug From Omeros for Up to $2.1 Billion -- Update

15. Okt. 2025, 13:27 UTC

Akquisitionen, Fusionen, Übernahmen

Novo Nordisk to Pay Omeros Up to $2.1 Billion for Blood Disease Drug

9. Okt. 2025, 10:49 UTC

Akquisitionen, Fusionen, Übernahmen

Novo Nordisk to Acquire Akero Therapeutics for Up to $5.2 Billion

1. Okt. 2025, 08:54 UTC

Wichtige Markttreiber

Pharma Stocks in Europe Jump After White House Unveils Drug-Buying Site

22. Okt. 2025, 10:45 UTC

Ergebnisse

AI Stocks Aren't the Only Market Play. How -2-

22. Okt. 2025, 10:45 UTC

Ergebnisse

AI Stocks Aren't the Only Market Play. How Earnings Are Easing Recession Fears. -- Barrons.com

17. Okt. 2025, 10:10 UTC

Wichtige Markttreiber

Ozempic Maker Novo Nordisk Shares Fall as Trump Moves to Cut Price of Weight-Loss Drugs

15. Okt. 2025, 12:33 UTC

Akquisitionen, Fusionen, Übernahmen

Novo Nordisk: Omeros Could Recieve Up to Total of $2.1B Including Potential Milestones, Tiered Royalties

15. Okt. 2025, 12:32 UTC

Akquisitionen, Fusionen, Übernahmen

Novo Nordisk: Omeros Eligible to Receive $340M in Upfront and Near-Term Milestone Payments

15. Okt. 2025, 12:32 UTC

Akquisitionen, Fusionen, Übernahmen

Novo Nordisk Will Be Granted Exclusive Global Rights to Develop, Commercialise Zaltenibart in All Indications

15. Okt. 2025, 12:32 UTC

Akquisitionen, Fusionen, Übernahmen

Novo Nordisk, Omeros in Asset Purchase and License Pact for Omeros' Rare Blood and Kidney Disorder Drug

10. Okt. 2025, 16:19 UTC

Akquisitionen, Fusionen, Übernahmen

Bristol Myers Squibb Buys Private Biotech for $1.5 Billion. The Deal Wave Keeps Going. -- Barrons.com

10. Okt. 2025, 13:03 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Novo Nordisk's Akero Deal Makes Sense But Raises Questions -- Market Talk

9. Okt. 2025, 15:17 UTC

Akquisitionen, Fusionen, Übernahmen

Novo Nordisk Is Buying Akero Therapeutics. It's More Good News for Biotech Stocks. -- Barrons.com

9. Okt. 2025, 11:31 UTC

Akquisitionen, Fusionen, Übernahmen

Akero Therapeutics Stock Soars. Novo Nordisk Is Buying the Biotech for up to $5.2 Billion. -- Barrons.com

9. Okt. 2025, 10:34 UTC

Akquisitionen, Fusionen, Übernahmen

Novo Nordisk to Acquire Akero Therapeutics for Up to $5.2B

9. Okt. 2025, 10:07 UTC

Akquisitionen, Fusionen, Übernahmen

Novo Nordisk Says Metabolic Dysfunction-Associated Steatohepatitis is Closely Linked With Diabetes and Obesity

9. Okt. 2025, 10:05 UTC

Akquisitionen, Fusionen, Übernahmen

Novo Nordisk: Akero is Developing Treatment For Liver Disease Metabolic Dysfunction-Associated Steatohepatitis

9. Okt. 2025, 10:04 UTC

Akquisitionen, Fusionen, Übernahmen

Akero: Each CVR to Entitle Holder to Cash Payment of $6/Shr Upon Full U.S. Regulatory Approval of Efruxifermin for Treatment of Compensated Cirrhosis Due to MASH by June 30, 2031 >AKRO

9. Okt. 2025, 10:03 UTC

Akquisitionen, Fusionen, Übernahmen

Novo Nordisk To Buy Akero Therapeutics for $4.7B in Cash, Plus Potentially an Additional $500M

9. Okt. 2025, 10:01 UTC

Akquisitionen, Fusionen, Übernahmen

Novo Nordisk Agrees to Buy Akero Therapeutics For $54 a Share

7. Okt. 2025, 09:15 UTC

Market Talk

Novo Nordisk Consensus 2027 Sales Expectations Look Too High -- Market Talk

1. Okt. 2025, 09:05 UTC

Heiße Aktien

Stocks to Watch Wednesday: Nike, Lithium Americas, Arm, Occidental -- WSJ

29. Sept. 2025, 12:04 UTC

Market Talk

Novo Nordisk Faces Headwind as U.S Obesity Drugs Stall, Competition Rises -- Market Talk

22. Sept. 2025, 13:43 UTC

Akquisitionen, Fusionen, Übernahmen

Pfizer to Buy Weight-Loss Drug Developer Metsera for Up to $7.3 Billion -- Update

18. Sept. 2025, 12:30 UTC

Market Talk

Correction to Novo Nordisk Market Talk

18. Sept. 2025, 12:00 UTC

Market Talk

Novo Nordisk's Prospects Could Turn Around -- Market Talk

18. Sept. 2025, 08:55 UTC

Heiße Aktien

Stocks to Watch Thursday: Nvidia, PayPal, Novo Nordisk -- WSJ

Novo Nordisk A-S (Class B) Prognose

Kursziel

By TipRanks

9.53% Vorteil

12-Monats-Prognose

Durchschnitt 1,162.73 DKK  9.53%

Hoch 1,550 DKK

Tief 720 DKK

Basierend auf 11 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Novo Nordisk A-S (Class B) – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

11 ratings

7

Buy

2

Halten

2

Sell

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Novo Nordisk A-S (Class B)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
help-icon Live chat